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Table S1. Imputation signals prioritized for follow-up. SNPs genotyped in the follow-up data sets are denoted in bold. The rs identifiers are from 
dbSNP129. For 1000 Genomes Project SNPs not present in dbSNP129, the identifier is assigned as chr#:base_position. 
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rs62174866 2 165636359 Imputed 0.88 1.25 6.65e-06     
rs62174867 2 165637556 Imputed 0.88 1.25 6.65e-06     
rs62174869 2 165638824 Imputed 0.91 1.26 3.44e-06     
rs62174894 2 165645219 Imputed 0.90 1.25 6.54e-06     
chr2:165664609 2 165664609 Imputed 0.95 1.23 8.91e-06     
rs62174897 2 165666897 Imputed 0.92 1.27 1.41e-06 Failed QC Failed QC Failed QC Failed QC 
rs62174901 2 165696589 Imputed 0.93 1.28 9.01e-07     
chr2:165698134 2 165698134 Imputed 0.94 1.23 8.92e-06     
rs62174906 2 165716603 Imputed 0.93 1.24 6.66e-07 1.06 0.1077 98.67% 99.30% 
           
rs3770123 2 182052466 Imputed 0.84 1.19 5.21e-06 Failed QC Failed QC Failed QC Failed QC 
rs10172410 2 182060813 Imputed 0.90 1.19 2.90e-07 1.01 0.7498 75.70% 77.92% 
           
rs4524693 7 44320782 Imputed 0.76 1.25 6.02e-06 Failed QC Failed QC Failed QC Failed QC 
rs4298415 7 44320790 Imputed 0.76 1.25 6.02e-06 Failed QC Failed QC Failed QC Failed QC 
chr7:44323325 7 44323325 Imputed 0.69 1.25 8.57e-06     
           
chr13:112732710 13 112732710 Imputed 0.94 1.35 8.74e-06     
chr13:112735818 13 112735818 Imputed 0.96 1.34 7.20e-06     
chr13:112736747 13 112736747 Imputed 0.96 1.34 7.16e-06     
chr13:112739547 13 112739547 Imputed 0.97 1.34 7.08e-06     
rs11842874 13 112742510 Genotyped 0.97 1.34 6.91e-06 1.17 2.60e-03 99.76% 98.21% 
rs1888227 13 112743230 Imputed 0.97 1.35 6.75e-06 1.09 0.0951 99.86% 98.90% 
chr13:112743781 13 112743781 Imputed 0.97 1.35 6.65e-06     
chr13:112745056 13 112745056 Imputed 0.87 1.41 3.49e-06     
           
rs12891775 14 95393018 Imputed 0.55 1.93 2.33e-06     
rs61983843 14 95398015 Imputed 0.55 1.93 2.28e-06     
rs35074918 14 95404536 Imputed 0.55 1.93 2.18e-06 1.02 0.7193 92.91% 33.54% 
rs61984878 14 95408354 Imputed 0.55 1.93 2.15e-06 1.03 0.6198 92.84% 33.64% 
rs34767699 14 95423877 Imputed 0.44 1.94 4.82e-06     
rs12888779 14 95425917 Imputed 0.42 1.97 5.46e-06     
           
rs12915297 15 61591608 Imputed 0.90 1.17 5.23e-06     
rs34675318 15 61954151 Imputed 0.97 1.17 5.56e-06 1.03 0.2474 92.66% 99.10% 
Acknowledgements 
arcOGEN is funded by a special purpose grant from Arthritis Research UK (grant 18030). This study used 
genotype data from population controls that was generated by the Wellcome Trust Case Control 
Consortium 2 (http://www.wtccc.org.uk), funded by The Wellcome Trust (grant 083948). The population 
controls were from the 1958 British Birth Cohort collection funded by the Medical Research Council 
(grant G0000934) and The Wellcome Trust (grant 068545) and from the UK National Blood Donor 
Service funded by The Wellcome Trust. The collection of GOAL samples was funded by Astra Zeneca UK.  
The author affiliated with AstraZeneca is an employee of AstraZeneca, a global research-based 
biopharmaceutical company focused on discovering, developing and marketing medicines for some of 
the world’s most serious illnesses, and owns stocks or stock options and has a pending patent 
application in the company.  The amplification, genotyping and analysis of the GOAL samples was 
funded by the EU FP7 programme grant 200800 “TREAT-OA”. The Rotterdam Study is funded by 
Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health 
Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (014-93-015; 
RIDE2), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the 
Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) project 
nr. 050-060-810, the European Commission (DG XII), and the Municipality of Rotterdam. The generation 
and management of GWAS data for the Rotterdam Study are supported by the Netherlands 
Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012). The 
Rotterdam Study is grateful to the study participants, the staff from the Rotterdam Study and the 
participating general practitioners and pharmacists.  The Rotterdam Study thanks Pascal Arp, Mila 
Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters for their help in creating the GWAS 
database, and Maksim V. Struchalin for his support in creation and analysis of imputed data. The 
Rotterdam Study would also like to thank Dr. Tobias A. Knoch, Anis Abuseiris, Luc V. de Zeeuw, and Rob 
de Graaf (Erasmus MC Rotterdam, The Netherlands), for their help in creating GRIMP, and BigGRID, 
MediGRID, and Services@MediGRID/D-Grid, (funded by the German Bundesministerium fuer Forschung 
und Technology; grants 01 AK 803 A-H, 01 IG 07015 G) for access to their grid computing resources. The 
EGCUT study received support from FP7 grants (201413 ENGAGE, 212111 BBMRI, OPENGENE) and 
targeted financing from Estonian Government SF0180142s08 and by the EU via the European Regional 
Development Fund, in the frame of Centre of Excellence in Genomics. The deCODE Genetics OA project 
is funded in part by the European Commission framework 7 programme TREAT-OA (grant 200800).  The 
authors that are affiliated with deCODE genetics are all employees of deCODE, a biotechnology company 
that provides genetic testing services, and some own stocks or stock options in the company. Newcastle 
investigators acknowledge the support of the UK NIHR BRC for Ageing and Age-related disease award to 
the Newcastle upon Tyne Hospitals NHS Foundation Trust. A.G.D-W, L.S, K.P. and E.Z are supported by 
the Wellcome Trust (WT088885/Z/09/Z). We would like to acknowledge Richard Durbin for useful 
comments on the manuscript. 
 
